CORE-CLINICAL/PATHOLOGICAL

由于阿尔茨海默氏症仍然是一种独特的人类疾病，这两种AD 研究需要病人磨砂他们的组织。临床-- 病理核心将为计划项目提供这项服务 调查人员应达到以下具体目标。在具体目标中1 和2，40名新的非裔美国人和40名新的白人AD患者和他们的 将确定并招募家庭参加黑利博士的 项目和参与纵向评价。此外, 招募了两个人群，即83名AD患者，抑郁症患者和正常对照组 在1987-1990年间，43名非裔美国精神错乱患者随后 Haley博士将继续进行纵向评估，以确定他们的 神经学、精神病学和神经心理学功能。就像许多人 这些患者都是严重受损的，无论是在家中还是在养老院 建议进行考试。在《特定目标3》中，一种新的神经心理学 为严重受损患者开发的电池将于 具体目标一、具体目标4中的数据 将通过以下方式管理和分析临床人群收集的数据 数据管理股。在具体目标5中，将要求对所有 计划项目主题以及将这些主题带入 尸检仍在继续。在特定的目标6中，所有的大脑都将经历 标准化解剖，并进行神经病理诊断，有待于 分发给计划项目调查员或为其存储。具体而言 目的7人海马区突触前标志物(SAP90、SAP97)的分析 将与项目3一起执行。

Since Alzheimer's Disease remains a uniquely human illness, both AD patients sand their tissues are needed for research studies. The Clinical- Pathological Core will provide this service for Program Project Investigators by meeting the following Specific Aims. In Specific Aims 1 and 2, 40 new African-American and 40 new White AD patients and their families will be identified and recruited for participation in Dr. Haley's Project and for participation in longitudinal evaluations. In addition, two populations, i.e., 83 AD, depressed and normal controls recruited between 1987-1990, and 43 African-American demented patients followed by Dr. Haley, will continue longitudinal evaluations to characterize their neurological, psychiatric and neuropsychological functions. As many of these patients are quite severely impaired, in-home or nursing home examinations are proposed. In Specific Aim 3, a new neuropsychological battery for severely impaired patients will be developed and validated on the populations followed in Specific Aim I. In Specific Aim 4, data collected on the clinical populations will be managed and analyzed via the Data Management Unit. In Specific Aim 5, autopsies will be sought on all Program Project subjects and the mechanisms to bring these subjects to autopsy continued. In Specific Aim 6, all brains will undergo a standardized dissection, with neuropathological diagnosis performed, to be distributed to or stored for Program Project Investigators. In Specific Aim 7, analyses of presynaptic markers (SAP90, SAP97) in human hippocampus will performed in conjunction with Project 3.